|
|
Post by radgray68 on Dec 11, 2019 11:30:00 GMT -5
NOT A LONG TERM INSULIN WHAAAAAAT?  ?!!!! ! Since when in the holy f--- have you seen this kind of BS? That translation can't be right. Right? |
|
|
|
Post by ktim on Dec 11, 2019 11:36:12 GMT -5
You’d first need Brazilians to be aware that Afrezza exists. Who’s going to spend money on marketing to make them aware? Press Release “Upon satisfactory approval from these regulatory bodies, MannKind will manufacture and supply Afrezza to Biomm, and Biomm will be responsible for promoting and distributing Afrezza within Brazil.” The best we can hope for is internet ads. The question is, can Biomm be more creative with the message, not being under the FDA’s heel? Has it been revealed exactly how much afrezza Biomm bought for $700,000? How much of a profit margin will they be able to achieve? As I understand it, they are a small company. Will they be able to build the infrastructure necessary to sell and distribute afrezza? All questions that no one here would know the answers to. |
|
|
|
Post by ktim on Dec 11, 2019 11:40:37 GMT -5
NOT A LONG TERM INSULIN WHAAAAAAT? ?!!!! ! Since when in the holy f--- have you seen this kind of BS? That translation can't be right. Right? I think it should read long-acting, so that might be translation problem. Obviously it's referring to basal insulin as can be seen in sentence that follows. T2 patients are typically first put on basal insulin. Some patients may see marketing for Afrezza and think "Wow, I'd rather inhale than have to shoot myself up!" That is directed at them, saying Afrezza isn't a replacement for your basal shots. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 11, 2019 12:14:08 GMT -5
I don’t think the object with Brazil is profit. In fact the lower the price as long as it is above break even on cost to produce the better imho as there is no way to make a reasonable profit and have it succeed. Higher price creates same problem as here, Afrezza becomes unavailable for too many who would otherwise use it. The goal here is to sell as much as mnkd can. The increase in production will lower average unit cost and increase profits as a result. And the more they sell in Brazil the more well known Afrezza will become in the rest of the world including here in the US. GLTAL’s!!!! Mike has said many times that Brazil was not going to be a huge profit center. He said it will help in utilizing their manufacturing facility while making a small profit. The only profitable market is the US. And don't expect a lot of profits out of India or China. |
|
|
|
Post by radgray68 on Dec 11, 2019 12:16:27 GMT -5
NOT A LONG TERM INSULIN WHAAAAAAT? ?!!!! ! Since when in the holy f--- have you seen this kind of BS? That translation can't be right. Right? I think it should read long-acting, so that might be translation problem. Obviously it's referring to basal insulin as can be seen in sentence that follows. T2 patients are typically first put on basal insulin. Some patients may see marketing for Afrezza and think "Wow, I'd rather inhale than have to shoot myself up!" That is directed at them, saying Afrezza isn't a replacement for your basal shots. I sure hope you're right about the translation. I think I'm not alone, though, in always looking for the next way the system will screw us over. This just startled me a little this morning. Im of the mind that if new diabetics start with inhaled insulin they'll see needles as archaic. But what do I know. |
|
|
|
Post by nylefty on Dec 11, 2019 13:41:46 GMT -5
Hopefully Brazilians will at least enjoy it and spread the word to buy MNKD stock. You’d first need Brazilians to be aware that Afrezza exists. Who’s going to spend money on marketing to make them aware? Press Release “Upon satisfactory approval from these regulatory bodies, MannKind will manufacture and supply Afrezza to Biomm, and Biomm will be responsible for promoting and distributing Afrezza within Brazil.” The best we can hope for is internet ads. The question is, can Biomm be more creative with the message, not being under the FDA’s heel? Brazil, like almost all countries, doesn't allow advertising of prescription drugs to consumers.
|
|
|
|
Post by castlerockchris on Dec 11, 2019 13:47:10 GMT -5
It's already started in Brasil!!!!!  Insulina Inalável AFREZZA | Resumão da Biabética www.youtube.com/watch?v=WvOOmmuR1QMI love that they inserted an applauds track when she finished demonstrating how to use Afrezza. |
|
|
|
Post by louaboardalia on Dec 11, 2019 13:48:32 GMT -5
Even if this is a break-even proposition, it might permit Mannkind to satisfy it's revised insulin purchase requirements from Amphastar, in addition to increasing production efficiencies. Thoughts?
|
|
|
|
Post by mytakeonit on Dec 11, 2019 13:50:32 GMT -5
The ad worked for me. I watched the whole thing and didn't understand a word she said. Except at the end where she said, "I miss you ... see you soon!" But, that's mytakeonit |
|
|
|
Post by buyitonsale on Dec 11, 2019 14:33:34 GMT -5
$700,000 order by BIOMM last quarter did not hurt MNKDs bottom line... I am sure the price they paid per box is in line with the pricing that came out...
If only 5% of diabetics in Brazil start using Afrezza and even if MNKD gets $12 per box times 12 months ($144 per year), it could bring in about $80M per year of revenue.
The only ones loosing money on Brazil's business will be short sellers.
|
|
|
|
Post by celo on Dec 11, 2019 15:04:11 GMT -5
I have a concern and a gripe about the Brazil news.
The concern has to do with how complicated/different from sub afrezza is. It has taken VDEX, a solid Facebook page with many very helpful diabetics and countless other individuals to pass information on how to properly dose and use afrezza. It has taken a lot of work by a lot of people. And the retention rate is still lower than it should be. Who is counseling all these new diabetics in Brazil on how to use afrezza? I believe Mannkind has come a long way in increasing it's efficacy, but you better start on the right foot with all these Brazilians who have taken a big interest.
The gripe is I pay 1400.00 a month for a high deductible HSA insurance plan. and now I know why. It is completely unfair to the people of the US that we pay so much for medications and therefore insurance. I know not all medications are priced with such a discrepancy and there are probably some generics that are cheeper here, but come on?
I wish all Brazilians and Mannkind all the best of luck, but realize Afrezza ain't easy.
|
|
|
|
Post by robbmo on Dec 11, 2019 15:16:12 GMT -5
Does anyone know if they can immediately start selling/filling prescriptions, or is there more ramp-up/waiting time?
|
|
|
|
Post by matt on Dec 11, 2019 15:39:55 GMT -5
Does anyone know if they can immediately start selling/filling prescriptions, or is there more ramp-up/waiting time? I think that the pricing was the last requirement; ANVISA approved the drug back in May. Most diabetics in Brazil get their insulin, which is supplied by government owned non-profit production centers, at the "Farmacia Popular" where the drugs are free. The trick is to get distribution in the pharmacies that are full service, for profit centers, and to get physicians to write scripts. I noted that there was no PMVG price announced which suggests the government will not be buying Afrezza for the Farmacia Popular. |
|
|
|
Post by peppy on Dec 11, 2019 16:06:13 GMT -5
Does anyone know if they can immediately start selling/filling prescriptions, or is there more ramp-up/waiting time? I think that the pricing was the last requirement; ANVISA approved the drug back in May. Most diabetics in Brazil get their insulin, which is supplied by government owned non-profit production centers, at the "Farmacia Popular" where the drugs are free. The trick is to get distribution in the pharmacies that are full service, for profit centers, and to get physicians to write scripts. I noted that there was no PMVG price announced which suggests the government will not be buying Afrezza for the Farmacia Popular. 8U X 90 70.63 ($17.14) 12U X 90 105.95 ($25.71) 4U X 60, 8U X 30 47.09 ($11.43) 4U X 30, 8U X 60 58.86 ($14.29) 8U X 60, 12U X 30 82.41 ($20.00) 4U X 90, 8U X 90 105.95 ($25.71) 1 Brazilian Real equals 0.24 United States Dollar ====================================================================================== The trick is to get distribution in the pharmacies that are full service, for profit centers, and to get physicians to write scripts. The trick is to get distribution on the Black Market for profit centers and physicians? |
|
|
|
Post by ktim on Dec 11, 2019 16:13:01 GMT -5
$700,000 order by BIOMM last quarter did not hurt MNKDs bottom line... I am sure the price they paid per box is in line with the pricing that came out... If only 5% of diabetics in Brazil start using Afrezza and even if MNKD gets $12 per box times 12 months ($144 per year), it could bring in about $80M per year of revenue. The only ones loosing money on Brazil's business will be short sellers. Have you calculated how many decades it would take to achieve $80M in revenue at $144/pt-yr if uptake were similar to US? Brazil's a good thing primarily as more opportunity for word of mouth and awareness. Though, It will be interesting to see what the adoption rate is. One could theorize that perhaps without the "stink" and misinformation from the botched SNY roll out that things might go better, though I'm not familiar with what a "good" roll out in Brazil would look like for adoption rates, since they don't allow advertising I'd imagine it's a very different dynamic. If it were to perform similar to other products such as when the RAAs were introduced, I'd take that as a good omen for opportunities in international markets where there is actually money to be made. |
|
